Exploration of Multiple Signaling Pathways Through Which Sodium Tanshinone IIA Sulfonate Attenuates Pathologic Remodeling Experimental Infarction.
AMP kinase pathway
apoptosis
autophagy
cardiac remodeling
sodium tanshinone IIA sulfonate
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2019
2019
Historique:
received:
18
09
2018
accepted:
17
06
2019
entrez:
30
7
2019
pubmed:
30
7
2019
medline:
30
7
2019
Statut:
epublish
Résumé
The level of maladaptive myocardial remodeling consistently contributes to the poor prognosis of patients following a myocardial infarction (MI). In this study, we investigated whether and how sodium tanshinone IIA sulfonate (STS) would attenuate the post-infarct cardiac remodeling in mice model of MI developing after surgical ligation of the left coronary artery. All mice subjected to experimental MI or to the sham procedure were then treated for the following 4 weeks, either with STS or with a vehicle alone. Results of our studies indicated that STS treatment of MI mice prevented the left ventricular dilatation and improved their cardiac function. Results of further tests, aimed at mechanistic explanation of the beneficial effects of STS, indicated that treatment with this compound enhanced the autophagy and, at the same time, inhibited apoptosis of the cardiomyocytes. Meaningfully, we have also established that myocardium of STS-treated mice displayed significantly higher levels of adenosine monophosphate kinase than their untreated counterparts and that this effect additionally associated with the significantly diminished activities of apoptotic promoters: mammalian target of rapamycin and P70S6 kinase. Moreover, we also found that additional administration of the adenosine monophosphate kinase inhibitor (compound C) or autophagy inhibitor (chloroquine) practically eliminated the observed beneficial effects of STS. In conclusion, we suggest that the described multistage mechanism triggered by STS treatment enhanced autophagy, thereby attenuating pathologic remodeling of the post-infarct hearts.
Identifiants
pubmed: 31354493
doi: 10.3389/fphar.2019.00779
pmc: PMC6639725
doi:
Types de publication
Journal Article
Langues
eng
Pagination
779Références
Pharmacol Res. 1999 Dec;40(6):487-91
pubmed: 10660946
Biomed Pharmacother. 2003 Jul-Aug;57(5-6):195-202
pubmed: 12888254
J Biol Chem. 2003 Oct 10;278(41):39653-61
pubmed: 12900407
J Mol Cell Cardiol. 2003 Sep;35(9):1063-71
pubmed: 12967629
Cell. 1992 Jun 26;69(7):1227-36
pubmed: 1377606
Cell. 2003 Nov 26;115(5):577-90
pubmed: 14651849
Circulation. 2004 Jun 22;109(24):3050-5
pubmed: 15184287
Mol Cell Biol. 2004 Jul;24(14):6231-40
pubmed: 15226426
Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13807-12
pubmed: 16174725
J Mol Cell Cardiol. 2006 Aug;41(2):256-64
pubmed: 16769083
Am J Physiol Heart Circ Physiol. 2007 May;292(5):H2184-94
pubmed: 17208988
Circ Res. 2007 Mar 30;100(6):914-22
pubmed: 17332429
Autophagy. 2008 Apr;4(3):322-9
pubmed: 18216495
J Cardiovasc Pharmacol. 2008 Apr;51(4):396-401
pubmed: 18427283
Acta Physiol (Oxf). 2009 May;196(1):65-80
pubmed: 19245654
Am J Pathol. 2009 May;174(5):1705-14
pubmed: 19342365
J Thorac Cardiovasc Surg. 2009 Jun;137(6):1356-62, 1362.e1-3
pubmed: 19464448
J Biol Chem. 2009 Dec 18;284(51):35839-49
pubmed: 19828446
J Am Coll Cardiol. 2009 Dec 15;54(25):2435-46
pubmed: 20082935
Am J Cardiol. 2010 Jan 1;105(1):59-63
pubmed: 20102891
Biochem Biophys Res Commun. 2011 Jan 28;404(4):1039-43
pubmed: 21187062
Am J Physiol Heart Circ Physiol. 2011 Jun;300(6):H2261-71
pubmed: 21421825
Autophagy. 2012 Apr;8(4):593-608
pubmed: 22441020
Evid Based Complement Alternat Med. 2012;2012:715790
pubmed: 22548119
Circ J. 2013;77(1):81-8
pubmed: 23018679
Br J Pharmacol. 2013 Jul;169(5):1058-71
pubmed: 23517194
Atherosclerosis. 2013 Sep;230(1):148-56
pubmed: 23958267
Eur Heart J. 2014 Jan;35(3):184-91
pubmed: 24104875
J Cell Biochem. 2014 May;115(5):996-1005
pubmed: 24356887
Exp Cell Res. 2014 Apr 15;323(1):189-97
pubmed: 24525372
Int J Cardiol. 2015 Mar 1;182:329-33
pubmed: 25585378
Front Physiol. 2015 Mar 04;6:66
pubmed: 25788886
Int J Cardiol. 2015 Oct 1;196:183-92
pubmed: 26143630
Am Heart J. 2015 Sep;170(3):550-8
pubmed: 26385039
Life Sci. 2015 Dec 1;142:8-18
pubmed: 26482204
Cardiovasc Drugs Ther. 2015 Dec;29(6):535-542
pubmed: 26482376
Biochem Biophys Res Commun. 2016 Oct 28;479(4):833-840
pubmed: 27693787
Toxicol Appl Pharmacol. 2017 Jan 1;314:82-90
pubmed: 27889531
Sci Rep. 2017 Feb 16;7:42843
pubmed: 28205629
Circ Heart Fail. 2017 Jul;10(7):
pubmed: 28694354
Front Physiol. 2018 May 22;9:589
pubmed: 29872406